The mice were bred on C57Bl6 background which also served as global controls throughout the study. Viability, fertility or breeding efficiency and nesting behaviour of the transgenic animals was not affected and the observed life span was not reduced. The presence of the transgenes was monitored by genotyping of the intersection of albumin promoter and SREBP-1a coding sequence. As mouse strains might have different expression levels of the transgenes due 
to physical integration of the construct in the genome, we decided to follow strains per genotype whose expression of transgene had a similar degree. In our SREBP-1a overexpressing mouse models the expression of the differential spliced SREBP-1a isoform SREBP-1c or SREBP-2 was not altered. Moreover the expression of endogenous SREBP-1a determined with mouse specific primers and probe was not altered in the transgenic mice, too. Western blot analyses of liver extracts for SREBP-1 protein indicate no alteration in the SREBP-1 precursor protein fraction in SREBP-1aDP, SREBP-1a and C57Bl6 mice. The total contend of nuclear SREBP-1 in liver extracts shown in western blot analyses with an SREBP-1 specific antibody detecting human and mouse SREBP-1 is increased in the transgenes order CEP32496 compared to C57Bl6. Using HA-tag specific antibody revealed the expression of the respective transgenes at the protein level to the same degree, too. Western blot analyses with extracts of liver, pancreas, heart, kidney, small intestine or skeletal muscle tissue proved that transgenes are expressed solely in liver of alb-SREBP1aDP or alb-SREBP-1a animals. To determine the functionality of the liverspecific overexpression of the human transcriptional active domain of SREBP-1a and the impact of SREBP-1aDP the gene expression of key metabolic enzymes was analyzed in liver of these animals as a functional proof of principle. The expression rates of genes involved in lipid metabolism like FAS, SCD or GPAT and the rate limiting gene in cholesterol metabolism, HMG-CoAR were at least doubled in alb-SREBP-1 aDP mice compared to C57Bl6 but increased more than 10 fold in alb-SREBP-1a PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/22189787 mice compared to C57BL6 mice. Genes involved in lipid transport as LDLR or ABCA1 were increased 2.5-fold in alb-SREBP-1 aDP mice and increased more than five- fold in alb-SREBP-1a mice. Interstingly Phosphorylation of SREBP-1a by JNK and p38 Kinases 6 Phosphorylation of SREBP-1a by JNK and p38 Kinases MTTP expression was not significantly altered in alb-SREBP-1 aDP but significantly increased in alb-SREBP-1 a mice. In SREBP-1 aDP PEPCK expression was elevated six-fold compared to a fifteen-fold increase in alb-SREBP-1 a mice. There was an approximately doubling of GLUT-2 expression in alb-SREBP-1a mice whereas the increase in alb-SREBP-1aDP was not significantly altered to C57Bl6. Rate limiting metabolic genes as liver specific pyruvate kinase or malic enzyme expression were significantly increased in alb-SREBP-1aDP compared to C57Bl6 but this again does not reach the increase observed in alb-SREBP1a animals. Taken together compared to C57Bl6 the effect of the phosphorylation deficient SREBP-1aDP is a clear inducibility of gene expression but the effect is by far not as pronounced as in the wildtype alb-SREBP-1a mice. Furhtermore for all genes investigated a significant increase of expression can be obtained also to SREBP-1aDP mice. Mutation of phosphorylation sites in SREBP-1a prevents excessive weight gain under normocaloric conditions Transgenic m
